secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACCENDRA HEALTH INC/VA/ (ACH)
CIK:        0000075252
Form:       8-K/A
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001104659-26-000614
Event type: m_and_a
Sentiment:  negative
Materiality: 0.75
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Accendra Health closes P&HS sale for $375M cash; pro forma revenue falls to $2.68B
--------------------------------------------------------------------------------

- Sold P&HS business for $375M cash on Dec 31, 2025; proceeds used to repay $280M current debt.
- Pro forma 2024 revenue $2.68B (vs $10.7B reported); net loss pro forma $366.5M vs $362.7M.
- Pro forma diluted EPS: 2024 -$4.78, 2023 -$0.15, 2022 -$0.72.
- Amended Receivables Sale Program: sold $94M eligible receivables, removed $160M intercompany payable.
- Retained a 5% equity interest in buyer with potential for up to $200M of priority distributions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/75252/000110465926000614/0001104659-26-000614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/75252/000110465926000614/omi-20251224x8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-000614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer